Optical Coherence Tomography Angiography Biomarkers that Predict Early Response to Anti-VEGF Therapy in Diabetic Macular Oedema.

Not Applicable

Completed

• Conditions: Diabetic Macular Oedema; Eye - Diseases / disorders of the eye; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12621001371886
• Lead Sponsor: ions Eye Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2021-09-30
• Study Start: 2021-10-11
• Last Update Posted: 18 October 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Age greater or equal to 18 years
Type 1 or 2 diabetes mellitus
Diabetic macular oedema (both treatment naive and previously treated) causing vision loss, with study eye BCVA measuring 0.3 to 1.0 logarithm of the minimum angle of resolution; macular oedema defined clinically and by retinal thickness of <250um in the central subfield; and intraretinal or subretinal fluid seen on SD-OCT.

Exclusion Criteria

Another concomitant ocular disease that causes macular oedema such as age-related macular degeneration or retinal vein occlusion.
Another ocular condition that compromises visual acuity, except for the presence of cataract.
Previous treatment with intraocular corticosteroids within the 6 months of the baseline visit.

Study & Design

• Study Type: Interventional
• Study Design: Not specified